A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma

Sponsor
Centocor, Inc.
Study ID
NCT00675649
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CNTO 148 / Golimumab — BIOLOGICAL
    100 mg sc injection every 4 weeks from week 0 to week 20
  • placebo — BIOLOGICAL
    placebo sc injection every 4 weeks from week 0 to week 20

Study Details

The purpose of this study is to assess the safety and effects (good and bad) of golimumab therapy in patients with severe, persistent asthma.

Key Dates

Start date
May 31, 2008
Status verified
Apr 2015

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 001
  • Placebo Comparator: 002

Primary Outcome Measure

The primary endpoint is the time to first severe asthma exacerbation through Week 24. [ Time Frame: Week 24 ]

Related Studies